癌症根治性术后新发持续阿片类药物使用
该研究利用2010至2014年全国保险理赔数据,纳入接受根治性手术的黑色素瘤、乳腺、结直肠、肺、食管及肝胰胆/胃癌患者共68463例,评估术后新发持续阿片类药物使用风险及每日剂量变化。在阿片未暴露患者中,新发持续使用风险为10.4%(95%CI 10.1%–10.7%),术后1年其每日剂量与慢性阿片使用者相似(P=.05)。
要点
- 阿片未暴露癌症患者根治性术后新发持续阿片使用风险为10.4%(95%CI 10.1%–10.7%)。
- 术后1年持续用药者每日剂量与慢性阿片使用者相似(P=.05),相当于每日6片5mg氢可酮。
- 接受辅助化疗者校正后新发持续使用风险为15%–21%,未化疗者为7%–11%。
核心结论
- 新发持续阿片类药物使用是接受根治性手术的癌症患者常见的医源性并发症。
- 该问题需要在监测与生存期照护阶段调整处方指南并加强患者宣教。
研究设计与样本
- 利用2010至2014年全国保险理赔数据库,识别接受根治性手术的癌症患者。
- 纳入黑色素瘤、乳腺、结直肠、肺、食管及肝胰胆/胃癌,共68463例符合条件并填写阿片处方者。
- 主要结局为新发持续阿片使用(阿片未暴露者术后90至180天仍持续取药)及术后1年内每月评估的每日阿片剂量,采用逻辑回归识别危险因素。
主要发现
- 阿片未暴露患者新发持续阿片使用风险为10.4%(95%CI 10.1%–10.7%)。
- 术后1年这些患者持续取药,每日剂量与慢性阿片使用者相似(P=.05),相当于每日6片5mg氢可酮。
- 接受辅助化疗者剂量略高(P=.002),但未化疗者剂量仍相当于每日5片5mg氢可酮。
- 不同术式中,接受辅助化疗者校正后新发持续阿片使用风险为15%–21%,未化疗者为7%–11%。
关键数值与推荐
- 新发持续阿片使用定义:阿片未暴露患者术后90至180天仍持续填写阿片处方。
- 阿片未暴露患者新发持续使用风险10.4%(95%CI 10.1%–10.7%)。
- 术后1年持续用药者每日剂量与慢性阿片使用者相似(P=.05),相当于每日6片5mg氢可酮。
- 辅助化疗者剂量略高(P=.002);未化疗者剂量相当于每日5片5mg氢可酮。
- 校正后新发持续使用风险:辅助化疗者15%–21%,未化疗者7%–11%。
临床怎么用
- 原文建议调整处方指南并在监测与生存期照护阶段加强患者宣教。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The current epidemic of prescription opioid misuse has increased scrutiny of postoperative opioid prescribing. Some 6% to 8% of opioid-naïve patients undergoing noncancer procedures develop new persistent opioid use; however, it is unknown if a similar risk applies to patients with cancer. We sought to define the risk of new persistent opioid use after curative-intent surgery, identify risk factors, and describe changes in daily opioid dose over time after surgery. Methods Using a national data set of insurance claims, we identified patients with cancer undergoing curative-intent surgery from 2010 to 2014. We included melanoma, breast, colorectal, lung, esophageal, and hepato-pancreato-biliary/gastric cancer. Primary outcomes were new persistent opioid use (opioid-naïve patients who continued filling opioid prescriptions 90 to 180 days after surgery) and daily opioid dose (evaluated monthly during the year after surgery). Logistic regression was used to identify risk factors for new persistent opioid use. Results A total of 68,463 eligible patients underwent curative-intent surgery and filled opioid prescriptions. Among opioid-naïve patients, the risk of new persistent opioid use was 10.4% (95% CI, 10.1% to 10.7%). One year after surgery, these patients continued filling prescriptions with daily doses similar to chronic opioid users ( P = .05), equivalent to six tablets per day of 5-mg hydrocodone. Those receiving adjuvant chemotherapy had modestly higher doses ( P = .002), but patients with no chemotherapy still had doses equivalent to five tablets per day of 5-mg hydrocodone. Across different procedures, the covariate-adjusted risk of new persistent opioid use in patients receiving adjuvant chemotherapy was 15% to 21%, compared with 7% to 11% for those with no chemotherapy. Conclusion New persistent opioid use is a common iatrogenic complication in patients with cancer undergoing curative-intent surgery. This problem requires changes to prescribing guidelines and patient counseling during the surveillance and survivorship phases of care.
引用
- Lee JS, Hu HM, Edelman AL, et al. New Persistent Opioid Use Among Patients With Cancer After Curative-Intent Surgery. J Clin Oncol. 2017. PMID: 29048972. doi:10.1200/JCO.2017.74.1363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。